Last reviewed · How we verify
Edema in cirrhotic patients unresponsive to fluid and sodium restriction — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aldactone | Spironolactone | Pfizer Inc. | Potassium-sparing diuretic, aldosterone antagonist | Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Edema in cirrhotic patients unresponsive to fluid and sodium restriction
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Edema in cirrhotic patients unresponsive to fluid and sodium restriction:
- Edema in cirrhotic patients unresponsive to fluid and sodium restriction treatment updates — RSS
- Edema in cirrhotic patients unresponsive to fluid and sodium restriction treatment updates — Atom
- Edema in cirrhotic patients unresponsive to fluid and sodium restriction treatment updates — JSON
Cite this brief
Drug Landscape (2026). Edema in cirrhotic patients unresponsive to fluid and sodium restriction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/edema-in-cirrhotic-patients-unresponsive-to-fluid-and-sodium-restriction. Accessed 2026-06-10.
Related
- Edema in cirrhotic patients unresponsive to fluid and sodium restriction full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing